Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain‐derived neurotrophic factor, β‐catenin and antidepressant‐like effects
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND PURPOSE: 5‐HT 2A receptor antagonists improve antidepressant responses when added to 5‐HT‐selective reuptake inhibitors (SSRIs) or tricyclic antidepressants. Here, we have studied the involvement of neuroplasticity pathways and/or the 5‐hydroxytryptaminergic system in the antidepressant‐like effect of this combined treatment, given subchronically. EXPERIMENTAL APPROACH: Expression of brain‐derived neurotrophic factor (BDNF) and its receptor (TrkB), 5‐bromo‐2′‐deoxyuridine (BrdU) incorporation, and β‐catenin protein expression in different cellular fractions, as well as 5‐HT 1A receptor function were measured in the hippocampus of rats treated with fluoxetine, ketanserin and fluoxetine + ketanserin for 7 days, followed by a forced swimming test (FST) to analyse antidepressant efficacy. KEY RESULTS: mRNA for BDNF was increased in the CA3 field and dentate gyrus of the hippocampus by combined treatment with fluoxetine + ketanserin. Expression of β‐catenin was increased in total hippocampal homogenate and in the membrane fraction, but unchanged in the nuclear fraction after combined treatment with fluoxetine + ketanserin. These effects were paralleled by a decreased immobility time in the FST. There were no changes in BrdU incorporation, TrkB expression and 5‐HT 1A receptor function in any of the groups studied. CONCLUSIONS AND IMPLICATIONS: The antidepressant‐like effect induced by subchronic co‐treatment with a SSRI and a 5‐HT 2A receptor antagonist may mainly be because of modifications in hippocampal neuroplasticity (BDNF and membrane‐associated β‐catenin), without a significant role for other mechanisms involved in chronic antidepressant response, such as hippocampal neuroproliferation or 5‐HT 1A receptor desensitization in the dorsal raphe nucleus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129
Nibuya, M., Morinobu, S., & Duman, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-11-07539.1995 · Cited by 2,109 · cited 5×
“…of the dentate gyrus (DG) of the hippocampus (Duman et al., 1997; Malberg et al., 2000; Santarelli et al., 2003), as well as an increase in the expression of brain-derived neurotrophic factor (BDNF) in the hippocampus (Nibuya et al., 1995; Vaidya et al., 1999) and serum (Shimizu et al., 2003).”
BackgroundInfluentialGuide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947 · cited 1×
“The effects of the neurotransmitter 5-HT are mediated by the 5-HT receptor family, formed by seven different subfamilies (5-HT1 to 5-HT7) and 13 different subtypes (for example, 5-HT2A/B/C; nomenclature follows Alexander et al., 2011).”
BackgroundShimizu, E., Hashimoto, K., Okamura, N., Koike, K., Komatsu, N., Kumakiri, C., Nakazato, M., Watanabe, H., Shinoda, N., Okada, S.-I., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00181-1 · Cited by 1,151 · cited 4×
“…of the dentate gyrus (DG) of the hippocampus (Duman et al., 1997; Malberg et al., 2000; Santarelli et al., 2003), as well as an increase in the expression of brain-derived neurotrophic factor (BDNF) in the hippocampus (Nibuya et al., 1995; Vaidya et al., 1999) and serum (Shimizu et al., 2003).”
BackgroundInfluentialInteraction between BDNF and Serotonin: Role in Mood Disorders
Martinowich, K., & Lu, B. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301571 · Cited by 793 · cited 1×
“It is noteworthy that BDNF is mainly involved in synaptic plasticity, rather than in neuron growth and survival (see Martinowich and Lu, 2008).”
BackgroundSerotonin model of schizophrenia: emerging role of glutamate mechanisms
Aghajanian, G. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00046-6 · Cited by 529 · cited 1×
“The role of 5-HT2A receptors is especially important in the prefrontal cortex where the activation of this receptor subtype produces an increase of the excitability of pyramidal neurons (Aghajanian and Marek, 2000).”
BackgroundUchida, N., Honjo, Y., Johnson, K. R., Wheelock, M. J., & Takeichi, M. (1996) · The Journal of cell biology · doi:10.1083/jcb.135.3.767 · Cited by 501
Cryan, J. F., Page, M. E., & Lucki, I. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0093-5 · Cited by 321
Rantamäki, T., Hendolin, P., Kankaanpää, A., Mijatovic, J., Piepponen, P., Domenici, E., Chao, M. V., Männistö, P. T., & Castrén, E. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301345 · Cited by 305
Marek, G. J., Carpenter, L. L., McDougle, C. J., & Price, L. H. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300057 · Cited by 275 · cited 15×
“Drugs that mediate both 5-HT reuptake inhibition and 5-HT2A receptor blockade are known as 5-HT2A receptor antagonists/ reuptake inhibitors (SARIs) and have been suggested in cases of treatment-resistant depression (Shelton et al., 2001; Marek et al., 2003; Adell et al., 2005).”
BackgroundInfluential
Cited by
Premenstrual Dysphoric Disorder: Epidemiology and Treatment
Hantsoo, L., & Epperson, C. N. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0628-3 · Cited by 329
The serotonin-BDNF duo: developmental implications for the vulnerability to psychopathology
Homberg, J. R., Molteni, R., Calabrese, F., & Riva, M. A. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.03.012 · Cited by 177
Galvão-Coelho, N. L., Marx, W., Gonzalez, M., Sinclair, J., de Manincor, M., Perkins, D., & Sarris, J. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05719-1 · Cited by 137
Neuroplasticity and the next wave of antidepressant strategies
Hayley, S., & Litteljohn, D. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00218 · Cited by 92
“More recently, augmentation of fluoxetine with the 5-HT2A receptor antagonist, ketanserin, induced a more potent increase of hippocampal BDNF mRNA and βcatenin protein (which is important for cellular proliferation and differentiation during development and repair) than either drug alone, and these effects coincided w…”
BackgroundYang, X.-H., Song, S.-Q., & Xu, Y. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s150028 · Cited by 84
Metadata
- Authors
- Pilar‐Cuéllar, F., Vidal, R., & Pazos, A.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2012-01-26
- Volume
- 165
- Issue
- 4b
- Pages
- 1046-1057
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1591013905
- Cited by
- 59
- References
- 14
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain‐derived neurotrophic factor, β‐catenin and antidepressant‐like effects. https://app.cochat.ai/papers/10.1111/j.1476-5381.2011.01516.x
- The paper
- Pilar‐Cuéllar, F., Vidal, R., & Pazos, A. (2012). Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain‐derived neurotrophic factor, β‐catenin and antidepressant‐like effects. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2011.01516.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.